Skip to content
Biodatica
Start free

Takeda

San Diego, California

OncologyPhase IIIListed · TAK

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase III trial registered: A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

4w agoTrial registeredJun 18, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Apr 13, 2026

    Hunter Syndrome · AVAILABLE · sponsor: Takeda · Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome

    ClinicalTrials.gov · NCT05795361 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Jun 13, 2025

    Refractory Lupus Nephritis, Refractory Systemic Sclerosis · WITHDRAWN · sponsor: Takeda · A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc)

    ClinicalTrials.gov · NCT06377228 (opens the source filing in a new tab)

  3. Trial

    PHASE3 registered

    May 6, 2025

    Myelodysplastic Syndromes · RECRUITING · sponsor: Takeda · A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

    ClinicalTrials.gov · NCT06499285 (opens the source filing in a new tab)

  4. Trial

    PHASE3 registered

    May 6, 2025

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) · RECRUITING · sponsor: Takeda · A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

    ClinicalTrials.gov · NCT06747351 (opens the source filing in a new tab)

  5. Trial

    PHASE1 registered

    Apr 22, 2025

    Healthy Volunteers · COMPLETED · sponsor: Takeda · A Study of TAK-881 With and Without Ramp-Up Dosing in Healthy Adults

    ClinicalTrials.gov · NCT06935266 (opens the source filing in a new tab)

  6. Trial

    PHASE1 registered

    Nov 1, 2024

    Healthy Volunteers · COMPLETED · sponsor: Takeda · A First-In-Human Study of TAK-004 in Healthy Adults

    ClinicalTrials.gov · NCT06236009 (opens the source filing in a new tab)

  7. Trial

    Study registered

    Sep 3, 2024

    Cytomegalovirus (CMV) · RECRUITING · sponsor: Takeda · A Study of Maribavir in Adults and Children With Post-transplant Cytomegalovirus (CMV) Infection in Argentina

    ClinicalTrials.gov · NCT06213974 (opens the source filing in a new tab)

  8. Trial

    PHASE1/PHASE2 registered

    May 20, 2024

    Ovarian Cancer, Solid Tumors · ACTIVE_NOT_RECRUITING · sponsor: Takeda · A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors

    ClinicalTrials.gov · NCT06390995 (opens the source filing in a new tab)

  9. Trial

    PHASE2 registered

    Mar 29, 2024

    Ulcerative Colitis · ACTIVE_NOT_RECRUITING · sponsor: Takeda · A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

    ClinicalTrials.gov · NCT06254950 (opens the source filing in a new tab)

  10. Trial

    PHASE3 registered

    Mar 19, 2024

    Generalized Pustular Psoriasis, Erythrodermic Psoriasis · ACTIVE_NOT_RECRUITING · sponsor: Takeda · A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

    ClinicalTrials.gov · NCT06323356 (opens the source filing in a new tab)

  11. Trial

    PHASE2/PHASE3 registered

    Apr 5, 2023

    Narcolepsy Type 1 · RECRUITING · sponsor: Takeda · A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

    ClinicalTrials.gov · NCT05816382 (opens the source filing in a new tab)

  12. Trial

    PHASE3 registered

    Aug 24, 2022

    Coagulation Disorder · RECRUITING · sponsor: Takeda · A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

    ClinicalTrials.gov · NCT05156983 (opens the source filing in a new tab)

  13. Trial

    Study registered

    Aug 8, 2022

    Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis · COMPLETED · sponsor: Takeda · A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland

    ClinicalTrials.gov · NCT05384080 (opens the source filing in a new tab)

  14. Trial

    Study registered

    Sep 8, 2021

    Inflammatory Bowel Diseases, Crohns Disease, Colitis, Ulcerative · COMPLETED · sponsor: Takeda · A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland

    ClinicalTrials.gov · NCT04989907 (opens the source filing in a new tab)

  15. Trial

    PHASE1/PHASE2 registered

    Mar 8, 2021

    Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer · TERMINATED · sponsor: Takeda · A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer

    ClinicalTrials.gov · NCT04844073 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources